ArticleNutrients2022
Towards a Common Definition for the Diagnosis of Iron Deficiency in Chronic Inflammatory Diseases.
Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Prevalence of iron deficiency in patients admitted to a geriatric unit: a multicenter cross-sectional study.BMC geriatrics · 2024Trial
- Review
- Iron Deficiency Screening in Patients Admitted with Acute Heart Failure Decompensation.Journal of cardiovascular translational research · 2026Article
- The Role of Reticulocyte-Derived Parameters in the Detection of Iron-Restricted Erythropoiesis in the Elderly.Diagnostics (Basel, Switzerland) · 2026Article
- Prevalence, Associated Factors, and Epidemiological Profile of Anemia Among Adults in a University Referral Hospital, Eastern Morocco.Epidemiologia (Basel, Switzerland) · 2026Article
- Iron deficiency in patients undergoing radiotherapy: Prevalence and clinical characteristics.Clinical and translational radiation oncology · 2026Article
- Expert Perspectives on Managing Iron Deficiency in People with CKD and/or HF.Journal of clinical medicine · 2026Article
- Characteristics of transferrin saturation and anemia-related biomarkers in patients with uterine adenomyosis.PloS one · 2026Article
- Early Haematologic Response to Oral Iron Treatment in Adults With Moderate Iron-Deficiency Anaemia.Anemia · 2025Article
- Association between CFTR modulators and changes in iron deficiency markers in cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024Article
- Use of Biomarkers of Inflammation in the Differentiation of Iron Deficiency and Anaemia-Lessons from Inflammatory Bowel Disease.Diagnostics (Basel, Switzerland) · 2024Article
- Laboratory tests for investigating anemia: From an expert system to artificial intelligence.Practical laboratory medicine · 2024Article
- Article
- Prognostic Value of Serum Transferrin Analysis in Patients with Ovarian Cancer and Cancer-Related Functional Iron Deficiency: A Retrospective Case-Control Study.Journal of clinical medicine · 2022Article
- Iron deficiency screening is a key issue in chronic inflammatory diseases: A call to action.Journal of internal medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
Abstract
Iron deficiency (ID) in patients with chronic inflammatory diseases is frequent. However, under-diagnosis is also frequent due to the heterogeneity between guidelines from different medical societies. We applied a common definition for the diagnosis of ID to a large panel of patients with cancer, heart failure (HF), inflammatory bowel disease (IBD), and chronic kidney disease (CKD), where ID was defined as serum ferritin concentration <100 μg/L and/or a transferrin saturation (TSAT) index <20%. Prevalence estimates using this common definition were compared with that obtained with officially accepted definitions (ESMO 2018, ESC 2016, ECCO 2015, and ERBP 2013). For that purpose, we used data collected during the French CARENFER studies, which included 1232, 1733, 1090, and 1245 patients with cancer, HF, IBD, and CKD, respectively. When applying the common definition, ID prevalence increased to 58.1% (vs. 57.9%), 62.8% (49.6%), and 61.2% (23.7%) in cancer, HF, and IBD patients, respectively. Both prevalence estimates were similar (47.1%) in CKD patients. Based on our results, we recommend combining both ferritin concentration and TSAT index to define ID in patients with chronic inflammatory diseases. In those patients, adopting this common definition of ID should contribute to a better screening for ID, whatever the condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.